Senostic Gmbh

SeNostic GmbH is a biotechnology company specializing in early diagnosis of neurodegenerative disorders like Alzheimer’s, Parkinson’s, and Amyotrohic Lateral Sclerosis (ALS). Our proprietary SeedCycler® technology detects disease-specific biomarkers years before symptoms appear, offering high sensitivity and specificity. This platform aids in differential diagnosis, patient stratification, and drug discovery by screening therapeutic candidates that target protein aggregation. Our assays target biomarkers such as alpha-synuclein, amyloid-beta, tau, and TDP-43, with applications in clinical diagnostics and preclinical trials. SeNostic’s innovative approach provides crucial tools for the pharma and biotech sectors to develop targeted therapies and enhance clinical outcomes. SeNostic GmbH also produces and distributes high-quality recombinant proteins, essential for research and diagnostic applications, ensuring the reliability and precision of its cutting-edge neurodegenerative disease assays.